Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Primary Humoral Immunodeficiencies and Bronchiectasis in Adults

dc.contributor.authorSuárez Cuartín, Guillermo Rafael
dc.contributor.authorLores, Carmen
dc.contributor.authorGómez Olivas, José Daniel
dc.contributor.authorOscullo, Grace
dc.contributor.authorMartínez García, Miguel Ángel
dc.date.accessioned2026-02-19T11:27:47Z
dc.date.available2026-02-19T11:27:47Z
dc.date.issued2025-12-26
dc.date.updated2026-02-09T12:19:29Z
dc.description.abstractPrimary humoral immunodeficiencies are a heterogeneous group of disorders defined by quantitative and/or functional defects in one or more immunoglobulin classes, often with associated cellular immune abnormalities. Their link with bronchiectasis, whose prevalence varies across specific defects, is largely driven by recurrent respiratory infections. Selective Immunoglobulin-(Ig)A deficiency and IgG2 subclass deficiency are the most frequent forms, but common variable immunodeficiency (CVID) is the condition most often associated with bronchiectasis and is usually diagnosed earlier because of its characteristic phenotype. In contrast, the contribution of isolated IgA deficiency or selective IgG subclass deficiencies to bronchiectasis remains controversial. Other reported associations include X-linked agammaglobulinemia, selective IgM or IgG deficiency, and rarer entities such as selective IgE deficiency, unclassified hypogammaglobulinemia, specific antibody deficiency, specific polysaccharide antibody deficiency, and heavy- or light-chain deficiencies. Current bronchiectasis guidelines recommend measurement of serum immunoglobulins and IgG subclasses in patients with compatible features, recurrent infections, or no clear etiology before labeling disease as idiopathic. Identifying immunoglobulin defects is clinically important because they represent treatable traits. The potential role of emerging therapies such as the DPP1 inhibitor brensocatib in immunodeficiency-related bronchiectasis remains uncertain, and ongoing registries will be key to clarifying these relationships.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid41517428
dc.identifier.urihttps://hdl.handle.net/2445/227065
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm15010179
dc.relation.ispartofJournal of Clinical Medicine, 2025, vol. 15, issue. 1, p. 179
dc.relation.urihttps://doi.org/10.3390/jcm15010179
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationMalalties bronquialscat
dc.subject.classificationSíndrome del destret respiratori de l'adultcat
dc.subject.otherBronchial diseases
dc.subject.otherAdult respiratory distress syndromeeng
dc.titlePrimary Humoral Immunodeficiencies and Bronchiectasis in Adults
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
jcm-15-00179.pdf
Mida:
476.5 KB
Format:
Adobe Portable Document Format